论文信息 - Use of terbinafine in HIV‐positive subjects: pilot studies in onychomycosis and oral candidiasis

Use of terbinafine in HIV‐positive subjects: pilot studies in onychomycosis and oral candidiasis

Study 1. Eighteen HIV‐positive Caucasian homosexual men with initial positive fungal microscopy were recruited into this prospective, dual‐centre, open‐label study. They received a once‐daily oral dose of 250 mg terbinafine for 12 weeks.

[1] R. Schopf,et al. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection , 1995, BMJ.

[2] D. Denning,et al. Fluconazole‐resistant candidosis in an HIV cohort , 1994, AIDS.

[3] E. Evans,et al. Short term treatment of dermatophyte onychomycosis with terbinafine. , 1992, BMJ.

[4] D. Smith,et al. Fluconazole resistant candida in AIDS. , 1991, The Journal of infection.

[5] T. Jones,et al. Clinical efficacy and tolerability of terbinafine (Lamisil)—a new topical and systemic fungicidal drug for treatment of dermatomycoses , 1989, Clinical and experimental dermatology.

[6] Y. Clayton. In vitro activity of terbinafine , 1989, Clinical and experimental dermatology.

[7] B. Fisher,et al. Cutaneous Manifestations of the Acquired Immunodeficiency Syndrome , 1986, International journal of dermatology.

[8] I. Murray-Lyon,et al. Early warning skin signs in AIDS and persistent generalized lymphadenopathy , 1985 .